- Home
- EXEL vs TECH Comparison
EXEL vs TECH Comparison
Compare EXEL & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | TECH |
|---|---|---|
| Founded | 1994 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.4B |
| IPO Year | 2000 | 1995 |
Fundamental Metrics
Financial Performance| Metric | EXEL | TECH |
|---|---|---|
| Price | $57.57 | $72.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | $46.50 | ★ $71.82 |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | 57.95 | ★ 152.17 |
| EPS | ★ 1.60 | 1.16 |
| Revenue | $452,477,000.00 | ★ $1,215,039,000.00 |
| Revenue This Year | $13.61 | $2.49 |
| Revenue Next Year | $13.13 | $6.40 |
| P/E Ratio | ★ $35.76 | $62.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.76 | $43.20 |
| 52 Week High | $59.72 | $72.62 |
Technical Indicators
Market Signals| Indicator | EXEL | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 63.42 |
| Support Level | $54.38 | $72.11 |
| Resistance Level | $59.72 | $72.62 |
| Average True Range (ATR) | 1.50 | 0.16 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 55.36 | 94.56 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.